Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer

Abstract

The PI3K/Akt/mTOR (phosphatidylinositol 3 kinase/ Akt/mammalian target of rapamycin) signalling pathway is an established driver of oncogenic activity in human malignancies. Therapeutic targeting of this pathway holds significant promise as a treatment strategy. Everolimus, an mtor inhibitor, is the first of this class of agents approved for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. Everolimus has been associated with significant improvements in progression-free survival; however, it is also associated with increased toxicity related to its specific mechanism of action. Methods: A comprehensive review of the literature conducted using a focused medline search was combined with a search of current trials at http://ClinicalTrials.gov/. Summary tables of the toxicities of the various classes of PI3K/Akt/mTOR inhibitors were created. A broad group of Canadian health care professionals was assembled to review the data and to produce expert opinion and summary recommendations for possible best practices in managing the adverse events associated with these pathway inhibitors. Results: Differing toxicities are associated with the various classes of PI3K/Akt/mTOR pathway inhibitors. The most common unique adverse events observed in everolimus clinical trials in breast cancer include stomatitis (all grades: approximately 60%), noninfectious pneumonitis (15%), rash (40%), hyperglycemia (15%), and immunosuppression (40%). To minimize grades 3 and 4 toxicities and to attempt to attain optimal outcomes, effective management of those adverse events is critical. Management should be interdisciplinary and should use approaches that include education, early recognition, active intervention, and potentially prophylactic strategies. Discussion: Everolimus likely represents the first of many complex oral targeted therapies for the treatment of breast cancer. Using this agent as a template, it is essential to establish best practices involving and integrating multiple disciplines for the management of future PI3K/Akt/mTOR signalling pathway inhibitors.

Autophagy: controlling cell fate in rheumatic diseases

“…For example, inhibition of AKT signalling combined with inhibi tion of mTOR signalling, using combinations of AKT and mTOR inhibitors or dual PI3K-AKT and mTOR inhibitors, might be of value in promoting autophagy in OA. Novel monospecific and dual inhibitors of AKT, PI3K, mTORC1 and mTORC2 have been tested, or are currently being tested, in clinical trials for the treat ment of breast and other cancers [209][210][211][212][213][214][215][216][217] . Dual PI3K and mTOR inhibitors, and dual mTORC1 and mTORC2 inhibitors, had similar safety and tolerability profiles within each class of compound as well as to allosteric mTORC inhibitors in earlyphase clinical trials in this setting.…”

Effects of ginsenoside compound K combined with cisplatin on the proliferation, apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer

“…PI3K/Akt signal pathway plays an important role in the process of cell proliferation and apoptosis, and PI3K/ Akt signal pathway in most tumour cells is activated (Chia et al 2015). PI3K can cause the phosphorylation of Akt.…”

An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease

“…in the treatment of some human neoplasms in selected cases (early stage NSCLC [16], advanced renal cell carcinoma [17], hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer [18], Kaposi's sarcoma in renal-transplant recipients [19]) and in the prevention of transplant rejection [20,21]. mTOR exists as a part of two distinct protein complexes, named mTOR complex 1 (mTORC1) and mTOR complex 2.…”